VPT:CC - Ventripoint Announces Extension and Up Size of Non-Brokered Convertible Debenture Unit Private Placement
(TheNewswire)
Toronto, Ontario, October 3,2025 – TheNewswire - Ventripoint Diagnostics Ltd. (“ Ventripoint ” or the “ Corporation ”,TSXV:VPT) announces that it will seek approvalof TSX Venture Exchange (“ TSXV ” or the “ Exchange ”) toextend its previously announced non-brokered private placement(“ Offering ”) of unsecured convertible debentures (“ Debentures ”) toNovember 2, 2025. (See press releases dated August 26, 2025 andSeptember 3, 2025).
Ventripoint also announces that it will seek approvalof the TSXV to increase the size of the Offeringfrom $500,000 to $560,000.
Each Unit is comprised: of one (1) unsecuredconvertible debenture principal amount of $1,000 (“ Debentures ”)convertible into common shares (“ Common Shares ”) ofthe Corporation; and 9,000 common share purchase warrants(“ Warrants ”).
The Debentures are convertible into Common Shares ofthe Corporation at the option of the holder at any time prior tomaturity at a conversion price of $0.11 per Common Share (the“ ConversionPrice ”). E ach wholeWarrant will entitle the holder thereof to purchase one (1) CommonShare at a price of $0.14 until December 31, 2027.
The Debentures mature December31, 2027 and bear interest at the rate of tenper cent (10%) payable semi-annually in arrears in either cash or atthe option of the Corporation by issuance ofCommon Shares at a 20-day VWAP market price, determined at time ofpayment, subject to Exchange approval.
The Corporation will use the proceeds of the Offeringto fund operational costs related sales and marketing, additional keypersonnel, and general working capital purposes.
All securities issued and issuable pursuant to theOffering are subject to a hold period of four months plus one day fromthe date of closing of the Offering. The Offering is subject to finalapproval by the Exchange.
The securities offered will not beregistered under the U.S. Securities Act of 1933, as amended, and maynot be offered or sold in the United States absent a registrationstatement or an applicable exemption from the registrationrequirements. The press release shall not constitute an offer to sellor the solicitation of an offer to buy nor shall there be any sale ofthe securities in any State in which such offer, solicitation or salewould be unlawful.
About Ventripoint DiagnosticsLtd.
Ventripoint has become anindustry leader in the application of AI (Artificial Intelligence) toechocardiography. Ventripoint's VMS+ products are powered by itsproprietary knowledge-based reconstruction technology, which is theresult of a decade of development and provides accurate volumetriccardiac measurements equivalent to MRI. This affordable, gold-standardalternative allows cardiologists greater confidence in the management of their patients. Providing better care topatients serves as a springboard and basic standard for all ofVentripoint's products that guide our future developments. Inaddition, VMS+ is versatile and can be used with all ultrasoundsystems from any vendor supported by regulatory market approvals inthe U.S., Europe and Canada.
For further information, pleasecontact:
Hugh MacNaught
hmacnaught@ventripoint.com
604-671-4201
Neither the TSX Venture Exchange norits Regulation Services Provider (as that term is defined in thepolicies of the TSX Venture Exchange) accepts responsibility for theadequacy or accuracy of this news release.
Forward Looking Statements
This news release contains forward-looking statementsand forward-looking information within the meaning of applicablesecurities laws. The use of any of the words "expect","anticipate", "continue", "estimate","objective", "ongoing", "may","will", "project", "should","believe", "plans", "intends'' andsimilar expressions are intended to identify forward-lookinginformation or statements. The forward-looking statements andinformation are based on certain key expectations and assumptions madeby the Corporation. Although the Corporation believes that theexpectations and assumptions on which such forward-looking statementsand information are based are reasonable, undue reliance should not beplaced on the forward-looking statements and information because theCorporation can give no assurance that they will prove to becorrect.
Since forward-looking statements and informationaddress future events and conditions, by their very nature theyinvolve inherent risks and uncertainties. Actual results could differmaterially from those currently anticipated due to a number of factorsand risks. Factors which could materially affect such forward-lookinginformation are described in the risk factors in theCorporation's most recent annual management's discussion andanalysis that is available on the Corporation's profile on SEDAR+at www.sedarplus.ca. Readers are cautioned that the foregoing list of factors isnot exhaustive. The forward-looking statements included in this newsrelease are expressly qualified by this cautionary statement. Theforward-looking statements and information contained in this newsrelease are made as of the date hereof and the Corporation undertakesno obligation to update publicly or revise any forward-lookingstatements or information, whether as a result of new information,future events or otherwise, unless so required by applicablesecurities laws.
NOT FOR DISTRIBUTION TOUNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITEDSTATES
Copyright (c) 2025 TheNewswire - All rights reserved.